PSX
ABBV
ABT

TILTON GLENN F

Known title: DirectorCIK: 0001194624

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Phillips 66 Raises Dividend, JV Rebrands Forecourts. Phillips 66 announced an increase in its quarterly dividend, highlighting its financial position. Meanwhile, Warrenton Oil, a joint venture associated with the company, rebranded 18 FastLane forecourts. Despite these corporate developments, the stock declined while the broader market posted gains. The company remains a key focus for dividend-focused market participants.

this person other insiders at PSX

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.

this person other insiders at ABBV

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

Abbott Labs launches Ensure Max Protein as earnings preview approaches. Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.

this person other insiders at ABT

Transaction History

PSX▲ Buy$200K
ABBV▲ Buy$0
PSX▲ Buy$200K
ABBV▲ Buy$0
PSX▲ Buy$200K
PSX▼ Sell$4K
ABBV▲ Buy$0
PSX▲ Buy$200K
ABBV▲ Buy$0
ABT▲ Buy$0
PSX▲ Buy—
PSX▲ Buy$200K

We use analytics to understand how market-wall is used. No personal data is sold.